GATA6‑AS1 inhibits ovarian cancer cell proliferation and migratory and invasive abilities by sponging miR‑19a‑5p and upregulating TET2

Abstract

GATA6 antisense RNA 1 (GATA6-AS1) has been reported to be involved in the progression of several types of cancer. In the present study, the role of GATA6-AS1 in ovarian cancer (OC) was explored. Reverse transcription quantitative PCR was used to detect the expression of GATA6-AS1, microRNA (miR)-19a-5p and tet methylcytosine dioxygenase 2 (TET2) in OC and adjacent normal tissues. Furthermore, OC cells with GATA-AS1 either knocked down or overexpressed were established. The Cell Counting Kit-8 assay was used to evaluate cell proliferation and a Transwell assay was used to assess the migratory and invasive abilities of OC cells. A dual luciferase reporter gene assay was used to determine whether GATA6-AS1 and miR-19a-5p, and miR-19a-5p and TET2, may interact with each other. The results demonstrated that GATA6-AS1 expression level was decreased in OC tissues and cells compared with control groups. In addition, GATA6-AS1 overexpression significantly inhibited the proliferation and migratory and invasive abilities of OC cells, whereas GATA6-AS1 downregulation had the opposite effects. Furthermore, GATA6-AS1 adsorbed miR-19a-5p to repress its expression and GTA6-AS1 indirectly upregulated TET2 expression. Taken together, the findings from this study suggested that GATA6-AS1 could inhibit the proliferation and migratory and invasive abilities of OC cells via regulation of the miR-19a-5p/TET2 axis.

RNA epigenetic modifications in ovarian cancer: The changes, chances, and challenges

“…This finding suggests that YBX‐1 may serve as a potential target both for elucidating OC cisplatin resistance mechanisms and for exploring new intervention strategies. Xu et al showed that GATA6 antisense RNA 1 (GATA6‐AS1) inhibited OC progression through the miR‐19a‐5p/TET2 axis, and indicated that TET2 was significantly downregulated in OC tissues and cells (H. Xu, Wang, et al, 2021). Study also found that m 5 C‐related regulators have important effects on the prognosis of OC, and a prognostic model signature composed of the m 5 C regulators ALYREF, NOP2, and TET2, served to improve the early diagnosis and screening of OC (Xu et al, 2022).…”

The functions of long noncoding RNAs on regulation of F-box proteins in tumorigenesis and progression

“…Emerging evidence has revealed that linc01436 plays an oncogenic role in gastric cancer progression (142)(143)(144). Linc01436 repressed the expression of miR-585-3p and increased mitogen-activated protein kinase 1 (MAPK1) expression, which contributed to gastric cancer development (143).…”

“…Emerging evidence has revealed that linc01436 plays an oncogenic role in gastric cancer progression (142)(143)(144). Linc01436 repressed the expression of miR-585-3p and increased mitogen-activated protein kinase 1 (MAPK1) expression, which contributed to gastric cancer development (143). Similarly, linc01436 triggered gastric cancer progression through modulation of miR-513a-5p and apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1) (144).…”

“…Xu et al. reported that lincRNA GATA6-AS1 regulated invasive and migratory capacities and viability via binding to miR-19a-5p and increasing TET2 in ovarian cancer cells ( 145 ). LincRNA GATA6-AS1 promoted GATA6 expression and controlled the behaviors of lung cancer cells ( 146 ).…”

Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed

“…RNA-binding proteins (RBPs), a class of endogenous proteins that bind to mRNA, regulate a series of pathological processes in ovarian cancer (171). Therefore, both lncRNAs and RBPs could be a potential therapeutic target (172)(173)(174)(175)(176)(177)(178). Non-coding RNA miR-146b simultaneously inhibited EGFR and IL6-STAT3 signal pathways, resulting in a more excellent suppression of ovarian cancer cell migration (179).…”